CTC Alternative Strategies’s Zentalis Pharmaceuticals ZNTL Stock Holding History

CTC Alternative Strategies’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.3K	Buy	+12,500	New	+$32.3K	0.07%	77

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

CTC Alternative Strategies's ZNTL Position: Q1 2026 in Review

CTC Alternative Strategies opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 12,500 shares worth $29.3K. The stake represents 0.07% of the portfolio and ranks #77 among its holdings.

102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

CTC Alternative Strategies held 12,500 shares of Zentalis Pharmaceuticals worth $29.3K as of Q1 2026.
Zentalis Pharmaceuticals was a new CTC Alternative Strategies position in Q1 2026.
Zentalis Pharmaceuticals made up 0.07% of CTC Alternative Strategies's portfolio in Q1 2026, its #77 holding.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on CTC Alternative Strategies's 13F filing for Q1 2026, filed 21 May 2026.